129 related articles for article (PubMed ID: 31176624)
1. Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?
Montironi R; Cheng L; Scarpelli M; Cimadamore A; Montorsi F; Lopez-Beltran A
Eur Urol; 2019 Sep; 76(3):e69-e72. PubMed ID: 31176624
[No Abstract] [Full Text] [Related]
2. Reply to Rodolfo Montironi, Liang Cheng, Marina Scarpelli, Alessia Cimadamore, Francesco Montorsi, and Antonio Lopez-Beltran's Letter to the Editor re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667-75: How Does Circulating DNA Reach the Blood Stream?
Wyatt AW; Chi KN; Gleave ME
Eur Urol; 2019 Sep; 76(3):e73-e74. PubMed ID: 31167749
[No Abstract] [Full Text] [Related]
3. Re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol 2018;74:283-91.
Conteduca V; Gurioli G; De Giorgi U
Eur Urol; 2018 Sep; 74(3):e67-e68. PubMed ID: 29803584
[No Abstract] [Full Text] [Related]
4. Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2018.02.013.
Mehra N; Dolling D; de Bono J
Eur Urol; 2018 Sep; 74(3):e69-e70. PubMed ID: 29866468
[No Abstract] [Full Text] [Related]
5. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
6. Reply to Robert J. van Soest and Ronald de Wit's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono J
Eur Urol; 2017 Jan; 71(1):e11. PubMed ID: 27751730
[No Abstract] [Full Text] [Related]
7. Re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
Cronauer MV; Merseburger AS; Hoda MR
Eur Urol; 2017 Apr; 71(4):e105-e106. PubMed ID: 27663049
[No Abstract] [Full Text] [Related]
8. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019:75:285-93.
von Eyben FE; Bauman G
Eur Urol; 2020 Mar; 77(3):e67-e68. PubMed ID: 31300234
[No Abstract] [Full Text] [Related]
9. Re: Joaquin Mateo, Karim Fizazi, Silke Gillessen, et al. Managing Nonmetastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:285-93.
Rocco B; Sighinolfi MC
Eur Urol; 2020 Mar; 77(3):e69. PubMed ID: 31151677
[No Abstract] [Full Text] [Related]
10. Re: Fabian Lohaus, Klaus Zöphel, Steffen Löck, et al. Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease? Eur Urol 2019;75:548-51.
Dirix PR; Mercier C; Dirix LY
Eur Urol; 2019 Oct; 76(4):e101-e102. PubMed ID: 31255421
[No Abstract] [Full Text] [Related]
11. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
van Soest RJ; de Wit R
Eur Urol; 2017 Jan; 71(1):e9-e10. PubMed ID: 27746063
[No Abstract] [Full Text] [Related]
12. Re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
Roviello G; Generali D; Petrioli R
Eur Urol; 2017 Feb; 71(2):e55. PubMed ID: 27543166
[No Abstract] [Full Text] [Related]
13. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al.'s Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e51-2.
On Behalf Of Ema
Eur Urol; 2019 Mar; 75(3):e53. PubMed ID: 30658854
[No Abstract] [Full Text] [Related]
14. Reply to Marcus V. Cronauer, Axel S. Merseburger, and M. Raschid Hoda's Letter to the Editor re: Christof Bernemann, Thomas J. Schnoeller, Manuel Luedeke, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol 2017;71:1-3.
Steinestel J; Bernemann C; Schrader AJ; Lennerz JK
Eur Urol; 2017 Apr; 71(4):e107-e108. PubMed ID: 27647434
[No Abstract] [Full Text] [Related]
15. Reply to Joe O'Sullivan, Daniel Heinrich, Nicholas D. James, et al's Letter to the Editor re: The Case Against the European Medicines Agency's Change to the Label for Radium-223 for the Treatment of Metastatic Castration-resistant Prostate Cancer. Eur Urol 2019;75:e53.
Leibowitz-Amit R
Eur Urol; 2019 Jul; 76(1):e19. PubMed ID: 30928161
[No Abstract] [Full Text] [Related]
16. Reply to Giandomenico Roviello, Daniele Generali, and Roberto Petrioli's Letter to the Editor re: Johann S. de Bono, Matthew R. Smith, Fred Saad, et al. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.06.033.
de Bono JS
Eur Urol; 2017 Feb; 71(2):e56. PubMed ID: 27544577
[No Abstract] [Full Text] [Related]
17. Reply to Tuomas Mirtti and Tero Aittokallio's Letter to the Editor re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40. Clinical Utility of Trial-estimated Prognostic Models.
Seyednasrollah F; Mahmoudian M; Rautakorpi L; Hirvonen O; Laitinen T; Jyrkkiö S; Elo LL
Eur Urol; 2017 Sep; 72(3):e70-e71. PubMed ID: 28499619
[No Abstract] [Full Text] [Related]
18. Re: Katharina Beyer, Lisa Moris, Michael Lardas, et al. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. Eur Urol 2022;81:503-14.
Lei R; Li Y; Chen Y
Eur Urol; 2022 Sep; 82(3):e67. PubMed ID: 35644770
[No Abstract] [Full Text] [Related]
19. Re: Fatemeh Seyednasrollah, Mehrad Mahmoudian, Liisa Rautakorpi, et al. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer? Eur Urol. 2017;71:838-40.
Mirtti T; Aittokallio T
Eur Urol; 2017 Sep; 72(3):e68-e69. PubMed ID: 28499620
[No Abstract] [Full Text] [Related]
20. Re: Erik Bovinder Ylitalo, Elin Thysell, Emma Jernberg, et al. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response. Eur Urol 2017;71:776-87.
Heidegger I; Pichler R; Pircher A
Eur Urol; 2017 Oct; 72(4):e102-e103. PubMed ID: 28602201
[No Abstract] [Full Text] [Related]
[Next] [New Search]
